Treatment of Diabetes Mellitus Flashcards

1
Q

Identify the main organs, and hormones involved in control of blood glucose. When are they produced, where, and what is their effect ?

A
1) Pancreas
GLUCAGON
-When: When blood glucose is low
-Where: alpha cells and upper GI
-Effect: stimulate glycogen breakdown and gluconeogenesis

INSULIN

  • When: is blood glucose is high
  • Where: Beta cells
  • Effects: stimulates muscle and adipose tissue to uptake glucose redistributing Glut4 to the cell membrane

2) Liver
- Controls glucose levels through gluconeogenesis and glycogen synthesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Identify risk factors for type I diabetes.

A
  • Genetic prediposition
  • Exposure to viral infections
  • Diet
  • Vitamin D deficiency
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What proportion of beta cells need to be destroyed in order for clinical type 1 diabetes to present ?

A

• Clinical T1DM does not present until >80-90% of beta cells have been destroyed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Describe clinical features and their timeline in type 1 diabetes.

A
  • Clinical course of T1DM is characterised by the rapid onset of osmotic symptoms, including polyuria, polydipsia, nocturia, thirst, weight loss and fatigue along with hyperglycaemia (possibly also osmotic lens change), while being clinically dry, and having increased urinary ketones.
  • Two thirds of patients present with life-threatening diabetic ketoacidosis at diagnosis (DKA)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the main treatment option for type 1 diabetes ?

A

Insulin therapy (to replace deficient hormone)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

To what extent is genetic predisposition present in type 2 diabetes ?

A

Genetic predisposition may be present

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Identify risk factors for type 2 diabetes.

A
Metabolic syndrome (starts with energy imbalance, high food consumption, and low energy expenditure)
Stress
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe the pathology underlying type 2 Diabetes.

A
  • Fat deposits in visceral organs leads to altered insulin signalling, insulin resistance and beta cell damage
  • Often impaired insulin receptor signalling leads to insufficient transport of glucose into tissues
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What proportion of beta cells need to be destroyed in order for clinical type 2 diabetes to progress ?

A

• T2DM progresses when ~80-90% of beta cells fail

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the main treatment option for type 2 diabetes ?

A

• Principle for treatment: try to correct energy imbalance, increase sensitivity to insulin, increase natural insulin secretion, supplement with insulin, or decrease blood glucose

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

When is each type of diabetes usually diagnosed ?

A

Type 1- in childhood

Type 2- in over 30 year olds

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

To what extent are DM types 1 and 2 associated with excess body weight ?

A

Type 1- NOT associated with excess body weight

Type 2- YES associated with excess body weight

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

To what extent are DM types 1 and 2 associated with higher than normal ketone levels at diagnosis ?

A

Type 1- Often associated with higher than normal ketone levels at diagnosis

Type 2- Often associated with high blood pressure and/or cholesterol levels at diagnosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

To what extent can type 1 and 2 diabetes be controlled without medication ?

A

Type 1- Cannot be controlled without taking insulin

Type 2- Sometimes possible to come off diabetes medication

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe progression to type 2 diabetes.

A
  • T2DM - there is a natural progression from prediabetes to diabetes, due to disruption of individual’s ability to metabolise glucose
  • Individuals with prediabetes have lower insulin sensitivity that results in hyperinsulinemia (i.e. due to insulin resistance, plasma insulin has to increase). At the point where insulin resistance overcomes ability to make insulin, blood glucose begins to increase.
  • Diabetes progresses when the beta-cells are failing, resulting in low insulin secretion in combination with low insulin sensitivity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What amount of fasting plasma glucose indicates diabetes ? What amount of random glucose ?

A

• >7 mM Fasting plasma glucose = diabetes
OR
random glucose measurements about 11.1 mM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

How is blood glucose monitored ?

A

• Effective diabetes management is usually measured by self-monitoring of blood glucose through sampling capillary blood after a finger prick
-NICE recommends monitoring this 4 times a day for individuals with type 1 DM (one before each meal, and at bedtime)

2) HbA(1c) measurement is also used to diagnose diabetes and evaluate glucose levels over a longer time-frame

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

How is HbA(1c) measurement useful for measuring blood glucose ?

A

• HbA1c provides an integrated measure of control over the lifespan of red blood cells ~120 days – levels above 7% indicate diabetes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What range of glucose do we aim for in type 1 DM ?

A

• Aim in treating Type I diabetics - replacement therapy to normalize glucose levels 4-7 mM (pre- prandial/fasting).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

To what extent should individual glucose levels rise about 8 mM after a meal ?

A

• In normal individuals glucose level can rise higher than normal range 4-7 but should be <7.8 mM two hours after a meal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

At which blood glucose level will glucose be detected in the urine ?

A

• Blood glucose levels >10 mM will overload the renal capacity and be detected in the urine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Identify the main kinds of insulin formulations which exist. State the duration of action of each.

A
  • Rapid-acting soluble insulin: Insulin lispro, Insulin aspart, and Insulin glulisine- rapid onset (10-20 minutes) and short duration (2-5 hrs)
  • Isophane insulin (Neutral Protamine Hagedorn; NPH) is an intermediate- acting insulin
  • Insulin glargine is a longer acting designer Insulin
  • Insulin detemir is a long-acting designer insulin
  • Insulin degludec is a long-acting designer insulin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is the duration of action of insulin ?

A

• Durations of activity can be rapid-acting (within 15 min) to long-duration peakless forms (some active >24 hours)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

How is insulin administered ? Why ?

A
  • Insulin is administered parentally because it is a protein that would be destroyed/digested by the gut if taken orally.
  • For routine use it is given subcutaneously and by IV infusion in emergencies (only soluble forms)
  • Can be given as a continuous subcutaneous infusion (CSII), giving background insulin (but also “allows for adjustable boluses to cover ingested carbohydrates”
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Describe the main dissolution properties of the main formulations of insulin.

A
  • Insulin lispro, Insulin aspart, and Insulin glulisine- prevent dimer formation allowing more active monomers to be bioavailable
  • Isophane insulin (Neutral Protamine Hagedorn; NPH)- recipitates into suspensions which slowly dissolve
  • Insulin glargine- has decreased solubility at neutral pH - forms aggregates that slowly dissolve
  • Insulin detemir- had a FA, a fatty acid, which confers albumin binding, which slowly dissociates prolonging circulation
  • Insulin degludec- has a fatty acid, which results in multi-hexamer formation at injection site with slow release
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

What proportion of type 2 DM patients use insulin ?

A

1/3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Graph glucose infusion rate of the main types of insulin formations, over time.

A

Refer to slide 12

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

When are fixed dose insulin therapies used ?

A

• A fixed dose therapy (i.e. amount of insulin taken at each meal does NOT vary from day to day) can help to simplify the understanding of blood glucose results but does not offer the flexibility of how much carbohydrate patients choose to consume at each meal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

When are flexilble dose insulin therapies used ?

A
  • Flexible insulin therapy is used for patients that really understand glucose metabolism and gives patients more control of what they eat and how they balance their blood glucose levels but will take time and commitment to learn how best to adjust insulin doses
  • On a flexible insulin therapy patients choose how much insulin to inject at each meal and also allows doses to be varied in response to different carbohydrate quantities in meals
30
Q

What is the main adverse effect of insulin therapy ?

A

• Main adverse effect of insulin therapy is hypoglycemia but for patients that have difficulty achieving good glycemic control they may need to use an insulin pump

31
Q

Identify the main types of insulin therapy with regards to number and kind of doses per day.

A

1, 2, 3 injections/day

Basal-bolus

Insulin pump (CSII).

32
Q

State the number of injections, time of injections, suitability to DM types, formulations, meal time and content, and requirement of patient understanding for:
1, 2, 3, injections/day.

A

1, 2, 3 INJECTIONS/DAY

  • Number of injections: 1-3
  • Time of injections: Morning or at meals
  • Suitability: T2D
  • Formulations: Rapid-acting or short-acting insulin is mixed w/ intermediate insulin
  • Meal time and content: Fixed
  • Required patient understanding: More basic
33
Q

State the number of injections, time of injections, suitability to DM types, formulations, meal time and content, and requirement of patient for:
Basal-bolus therapy

A

BASAL-BOLUS

  • Number of injections: Multiple
  • Time of injections: Throughout the day
  • Suitability: T1D, some T2D
  • Formulations: Intermediate or long acting with short acting formulation
  • Meal time and content: Flexible
  • Required patient understanding: High
34
Q
State the number of injections, time of injections, suitability to DM types, formulations, meal time and content, and requirement of patient for:
Insulin Pump (CSII)
A

INSULIN PUMP (CSII)

  • Number of injections: semi-automated (as needed)
  • Time of injections: Throughout the day
  • Suitability: T1D
  • Formulations: Short acting insulin formulation
  • Meal time and content: Flexible
  • Required patient understanding: Medium/high
35
Q

Identify the main drugs used in type 2 DM.

A
ORAL HYPOGLYCEMIC AGENTS 
INCRETIN MIMETICS
DPP-4 INHIBITORS
INSULIN SECRETAGOGUES
SGLT2 INHIBITORS
THIAZOLINEDINEDIONES 
ALPHA GLUCOSIDATE INHIBITORS
36
Q

Identify an example of oral hypoglycemic agent. Describe its mechanism of action.

A

Metformin

•Mechanism of action: can potentiate residual insulin and insulin sensitivity + acts to reduce gluconeogenesis in the liver (markedly increased in type 2 DM and oppose the actions of glucagon) + increases glucose uptake and utilization in skeletal muscle + slightly delays carb absorption in the gut + increases FA oxidation + can encourage weight loss by suppressing appetite + alters energy metabolism

37
Q

How does increasing FA oxidation help metformin control type 2 DM ?

A

• Increases fatty acid oxidation - reduces circulating LDL and VLDL, which can help in obesity associated diabetes and atherosclerosis development

38
Q

Identify a possible side effect of Metformin.

A

In rare cases can cause anorexia

39
Q

Explain how Metformin alters energy metabolism. How quick or slow is this ?

A

METFORMIN alters energy metabolism:

  • Acts on the mitochondria to change ratio of AMP to ATP
  • Increased AMP:ATP ratios activate AMP-activated protein kinase (cells metabolic master switch)
  • This inhibits glucagon signaling and gluconeogenic pathways
  • AMPK increases transcription of genes important for glucose transport, fatty oxidation, and inhibits FA synthesis

TAKE TIME DUE TO REGULATION GENE NETWORKS

40
Q

What type of cells secrete GLP-1 ? GIP ?

A
  • Glucagon-like peptide-1 (GLP-1) is secreted by L-cells in the gut
  • Gastric inhibitory peptide (GIP) secreted by K-cells in gut
41
Q

What is the main action of incretins ?

A

• Incretins stimulate insulin biosynthesis/ secretion, inhibit glucagon secretion in pancreas, delay gastric emptying, increase cardiac output and increase brain satiety signals + also indirectly increase insulin sensitivity in muscle and decrease gluconeogenesis in liver

42
Q

How are incretins degraded ?

A

• Incretins are rapidly degraded by an enzyme called dipeptidyl peptidase-4 (DPP-4)I

43
Q

Identify the main examples of incretin mimetics. Which incretin does each of these mimic ?

A

• Exenatide, Exenatide LAR, and Liraglutide- analogs of exendin-4/GLP-1

44
Q

What is the main mechanism of action of incretin mimetics ? What is their route of administration?

A
  • Incretin analogs lowers blood glucose after a meal by increasing insulin secretion and suppressing glucagon secretion.
  • Given subcutaneously (SC) as peptide analogs.
45
Q

Identify side effects of incretin mimetics.

A

• Can cause hypoglycemia and a range of gastrointestinal effects.

46
Q

Identify main indications of incretin mimetics.

A

• Used for type 2 diabetes in addition to oral agents to improve control and aid weight loss.

47
Q

What are the main differences between Exenatide and Exenatide LAR ?

A
  • Exenatide is given twice daily, but can cause nausea

* Exenatide LAR is a long-acting release formulation that is administered weekly and induces less nausea

48
Q

What is the structural specificity of Liraglutide ? How does this aid its action ?

A

• Liraglutide has an additional fatty side-chain that confers albumin binding and slows renal clearance

49
Q

Identify examples of DPP-4 inhibitors.

A

• Sitagliptin and vildagliptin

50
Q

What is the mechanism of action of DPP-4 inhibitors ?

A
  • Enhance endogenous incretin effects by blocking DPP-4

* Lowers blood glucose by increasing first phase of insulin response after meals.

51
Q

What are the main indications for DPP-4 inhibitors ?

A

• Used in type 2 diabetes in addition to other oral hypoglycaemic drugs.

52
Q

Identify the side effects of the main DPP-4 inhibitors.

A
  • Sitagliptin is well tolerated and weight neutral.
  • Vildagliptin is not available in the USA - found associated with respiratory tract infections, headache and on occasion serious pancreatitis.
53
Q

Identify the main insulin secretagogues.

A

Sulphonylureas (e.g. Tolbutamide, Chlorpropamide, Glibenclamide, Glipizide)

Meglitinides (Repaglinide and Nateglinide)

54
Q

Describe the mechanism of action of Sulphonylureas, and Meglitinides.

A

SULPHONYLUREAS
• Sulphonylureas interfere with beta cell ion channels to potentiate insulin secretion.

MEGLITINIDES
• Similar mechanism of action as Sulphonylureas (blocking KATP channels to ↑insulin release)

55
Q

Identify the main indications of Suphonylureas.

A
  • Used in early stages of type 2 diabetes – as they require functional b cells
  • Can be combined with Metformin and Glitazones.
56
Q

Identify any side effects of Sulphonylureas, and Meglitinides.

A

SULPHONLUREAS
• Well tolerated but can lead to weight gain by stimulating appetite
• Can interact with other drugs to produce severe hypoglycaemia due to competition for metabolising enzymes, plasma binding proteins, and excretory pathways

MEGLITINIDES
• Short duration of activity leads to lower risk of hypoglycaemia

57
Q

State a condition which is required for Sulphonylureas to work.

A

Only work if b cells of the pancreas are functional.

58
Q

How do Sulphonylureas interfere with beta cell ion channels to potentiate insulin secretion ?

A
  • High affinity receptors for these drugs are present in b- cell membranes.
  • Block ATP-sensitive potassium channels in b- cells.
  • Causes beta cell depolarisation, which leads to insulin secretion.
59
Q

Identify examples of SGLT2 inhibitors.

A

• Canagliflozin, dapagliflozin, empagliflozin

60
Q

Identify indications for SGLT2 inhibitors.

A

Used in T2D as monotherapy when diet and exercise alone is not adequate for whom metformin is contraindicated or inappropriate.

61
Q

Describe mechanism of action of SGLT2 inhibitors.

A
  • Block glucose reabsorption by the proximal tubule leading to therapeutic glucosuria
  • Controls glycaemia independently of insulin pathways
  • Lead to reduced HbA1c up to 1.17% compared to placebo –
62
Q

Identify side effects of SGLT2 inhibitors.

A
  • Well tolerated, reduce weight and reduce systolic blood pressure
  • Do not cause hypoglycaemia but associated with increased risk of urinary tract infections
63
Q

Identify an example of Thiazolidinediones.

A

Pioglitazone

64
Q

What class of drugs do Thiazolidinediones belong to ?

A

Thiazolidinediones are Peroxisome proliferator activated receptor – gamma ( PPARgamma - a nuclear receptor) agonists

65
Q

Where is the Peroxisome proliferator activated receptor expressed ?

A

PPARgamma expressed in adipose tissue, muscle and liver.

66
Q

Identify the main indications for Pioglitazone.

A
  • Pioglitazone increases insulin sensitivity and lowers blood glucose in type 2 diabetics
  • Pioglitazone is used in the clinic as an additive to other oral hypoglycaemic drugs such as metformin and Sulphonylureas
67
Q

Describe mechanism of action of Pioglitazone.

A
  • Reduces the amount of exogenous insulin needed by about 30%
  • Increases glucose uptake into muscle in response to insulin
  • Reduces blood glucose and free fatty acid concentrations
  • Promote transcription of several genes with products that are important in insulin signalling ( lipoprotein lipase, fatty acid transporters, Glut-4 and others) but take months to work
68
Q

Identify side effects of Pioglitazone.

A
  • Can cause weight gain and fluid retention

* Has been linked to bladder cancer, heart failure, and osteoporotic fractures

69
Q

Identify an example of alpha-Glucosidase inhibitor.

A

Acarbose

70
Q

Describe the mechanism of action of Acarbose (an alpha-Glucosidase inhibitor).

A
  • Competitive inhibitor of intestinal alpha-glucosidase

* Delays carbohydrate absorption in the small intestine reducing the postprandial spike in glucose

71
Q

Identify the main indications for Acarbose (an alpha Glucosidase inhibitor).

A

Used in type 2 diabetes often in combination with other hypoglycaemics

72
Q

Identify side effects of Acarbose (an alpha Glucosidase inhibitor).

A

Side effects can include flatulence and diarrhea